Evaluating the efficacy and safety of adebrelizumab for the adjuvant treatment of esophageal squamous cell cancer.
HB≥90g/L；
ANC≥1.5×109/L；
PLT≥100×109/L；
ALT and AST<2.5ULN（liver metastasis: ALT and AST<5ULN）；
Patients initially diagnosed as unresectable (e.g. large metastatic lymph nodes) and treated with conversion therapy;
Patients with severe postoperative complications who are not suitable for adjuvant therapy;
Patients who have received any form of adjuvant therapy after surgery;
Patients who have received or are receiving other chemotherapy, radiotherapy or targeted therapy;